RANI (Rani Therapeutics) קצב צמיחת רווח למניה בשנה הנוכחית

Geopolitical instability and logistics disruptions are hindering medical tests, which correlates with the year-over-year percentage change in EPS, where the metric value stands at 62.80. Volatility is being mitigated by B2B licensing plans for the RaniPill system to drive expansion for Rani Therapeutics (RANI). Meanwhile, patent protection for the painless gastrointestinal delivery of biologics creates a significant moat in negotiations with industry behemoths.
פילוחים אנליטיים ודוחות נתונים של חברת Rani Therapeutics (RANI)

This indicator measures the annual growth of net income per share. By analyzing the relative EPS growth over 12 months, an investor assesses the efficiency of business scaling. The metric is calculated as the percentage deviation of the current value from the same period last year. It is highly sensitive to operating expenses; for Rani Therapeutics (RANI), this reflects the development costs of the RaniPill robotic pill.